1. ADVANCEDATA,
from Vital & Health Statistics of The National Center for Health
Statistics, US Department of Health and Education Welfare, No. 5,
February 22, 1977, Public Health Service- Health Resources Administration. “A
Comparison of Levels of Serum Cholesterol of Adults 18-74 Years of
Age in the Untied States in 1960-62 and 1971- 74.”
2. Mahanonda N, Leowattana W, Kangkagate C, Lolekha P, Pokum S.Homocysteine
and restenosis after percutaneous coronary intervention. J Med Assoc
Thai.2001 Dec;84 Suppl 3:S636-44.
3. Robinson K, Mayer EL, Miller DP, et al. Hyperhomocysteinemia
and low pyridoxal phosphate. Common and inde- pendent reversible risk
factors for coronary artery disease. Circulation. 1995 Nov 15;92(10):2825-30.
4. Tenover JS. Effects of testosterone supple- mentation in the
aging male. J Clin Endocrinol Metab. 1992 Oct;75(4):1092-8.
5. Phillips GB, Pinkernell BH, Jing TY. The association of hypotestosteronemia
with coronary artery disease in men. Arterioscler Thromb. 1994 May;14(5):701-6.
6. Gelfand MM, Wiita B. Androgen and estrogen-androgen hormone replacement
therapy: a review of the safety literature, 1941 to 1996. Clin Ther.
1997 May-Jun;19(3):383-404; discussion 367-8.
7. Gooren LJ Endocrine aspects of ageing in the male. Mol Cell Endocrinol.
1998 Oct 25;145(1-2):153-9.
8. Barrett-Connor E, Von Muhlen DG, Kritz- Silverstein D. Bioavailable
testosterone and depressed mood in older men: the Rancho Bernardo
Study. J Clin Endocrinol Metab. 1999 Feb;84(2):573- 7.
9. Schweiger U, Deuschle M, Weber B, et al. Testosterone, gonadotropin,
and cortisol secretion in male patients with major depression. Psychosom
Med. 1999 May- Jun;61(3):292-6.
10. Rabkin JG; Wagner GJ; Rabkin R. Testosterone therapy for human
immuno-deficiency virus-positive men with and with out hypogonadism.
J Clin Psychopharmacol. 1999 Feb;19(1):19-27.
11. Seidman SN, Walsh BT. Testosterone and depression in aging men.
Am J Geriatr Psychiatry. 1999 Winter;7(1):18-33.
12. The Testosterone Syndrome, Eugene Shippen and Fryer, W. P. 116.
13. Maximize Your Vitality & Potency, Jonathan Wright and Lenard,
L., pp. 146- 47.
14. Super T, Karlis Ullis, MD, Shackman, J, and Ptacek, G. pp. 43-44.
15. Tan RS, Pu SJ. The andropause and memo- ry loss: is there a
link between androgen decline and dementia in the aging male? Asian
J Androl. 2001 Sep;3(3):169-74.
16. Vanderpump MP, Tunbridge WM, French JM, et al. The incidence
of thyroid disorders in the community: a twenty-year follow-up of
the Whickham Survey. Clin Endocrinol (Oxf). 1995 Jul;43(1):55-68.
17. Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman
JC. Subclinical hypothyroidism is an independent risk fac- tor for
atherosclerosis and myocardial infarction in elderly women: the Rotterdam
Study. Ann Intern Med. 2000 Feb 15;132(4):270-8.
18. Michalopoulou G, Alevizaki M, Piperingos G, et al. High serum
cholesterol levels in persons with “high-normal” TSH levels:
should one extend the definition of subclin- ical hypothyroidism?
Eur J Endocrinol. 1998 Feb;138(2):141-45.
19. Pollock MA, Sturrock A, Marshall K, et al. Thyroxine treatment
in patients with symp- toms of hypothyroidism but thyroid func- tion
tests within the reference range: ran- domized double blind placebo
controlled crossover trial. BMJ. 2001 Oct 20;323(7318):891-5.
20. Bjelland I, Tell GS, Vollset SE, Refsum H, Ueland PM. Folate,
vitamin B12, homocysteine, and the MTHFR 677CT polymorphism in anxiety
and depression. The Hordaland Homocysteine Study. Archives of General
Psychiatry. 2003 Jun;60(6):618-26.
21. Koenig W, Sund M, Fröhlich M, et al. C- reactive protein,
a sensitive marker of inflammation, predicts future risk of coronary
heart disease in initially healthy middle-aged men. Results from the
MONICA (Monitoring Trends and Determinants in Cardiovascular Disease)
Augsburg Cohort Study, 1984 to 1992. Circulation. 1999 Jan 19;99(2):237-42
22. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridket PM. C-reactive
protein, interleukin 6, and risk of developing Type II diabetes mellitus.
JAMA. 2001 Jul 18;286(3):327-34.
23. Teunissen CE, van Boxel MP, Bosma H, et al. Inflammation markers
in relation to cog- nition in a healthy aging population. J Neuroimmunol.
2003 Jan (1-2);134:142-50.
24. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation
and cardiovas- cular disease: application to clinical and public health
practice: A statement for healthcare professionals from the Centers
for Disease Control and Prevention and the American Heart Association.
Circulation. 2003 Jan 28;107(3):499-511.
25. Catalona WJ, Partin AW, Slawin KM, et al. Use of percentage
of free prostate-specific antigen to enhance differentiation of prostate
cancer from benign prostatic dis- ease. A prospective multicenter
clinical trial. JAMA. 1998 May 20; 279(19):1542-7.
26. Punglia RS, D’Amico AV, Catalona WJ, Roehl KA, Karen M.,
Kuntz KM. Effect of verification bias on screening for prostate cancer
by measurement of prostate- specific antigen. N Engl J Med. 2003 Jul
24;349(4):335-42.
27. Reuters Health: Precursor of PSA accurate ly detects prostate
cancer. July 15, 2003.
28. Reuters Health: Exercise tougher at begin ning of menstrual
cycle. July 5, 2002.
29. Dinarello CA. Proinflammatory cytokines. Chest. 2000;118:503-508.
30. Kiecolt-Glaser JK, Preacher KJ, MacCallum RC, Atkinson C, Malarkey
WB, Glaser R. Chronic stress and age-related increases in the proinflammatory
cytokine IL-6. Proc Natl Acad Sci. 2003 Jul 22;100(15):9090-5.
31. Verdecchia P, Reboldi G, Porcellati C, et al. Risk of cardiovas
cular disease in relation to achieved office and ambulatory blood
pres- sure control in treated hypertensive sub- jects. J Am Coll Cardiol.
2002 Mar 6;39(5):878-85.
32. Mendall MA, Patel P, Asante M, et al. Relation of serum cytokine
concentrations to cardiovascular risk factors and coronary heart disease.
Heart. 1997 Sep;78(3):273-7.
33. Lappe JM, Muhlestein JB, Carlquist JF, Davis BF, Horne BD, Anderson
JL. Inlerleukin-1 beta predicts death or myocardial infarction independently
of high-sensitivity C-reactive protein and stan- dard risk factors
in patients with coronary artery disease. Abstracts – Myocardial
Ischemia and Infarction 841-2. J Am Coll Cardiol. 2002.
34. Brambilla F, Bellodi L, Perna G, Bertani A, Panerai A, Sacerdote
P. Plasma Interleukin-1beta concentrations in panic disorder. Psychiatry
Res. 1994 Nov;54(2):135-42.
35. Ishimi Y, Miyaura C, Jin CH, Akatsu T, Abe E, Nakamura Y, Yamaguchi
A, Yoshiki S, Matsuda T, Hirano T, et al. IL-6 is pro- duced by osteoblasts
and induces bone resorption. J Immunol. 1990 Nov 15;145(10):3297-303.
36. Lou W, Ni Z, Dyer K, Tweardy DJ, Gao AC. Interleukin-6 induces
prostate cancer cell growth accompanied by activation of stat3 signaling
pathway. Prostate. 2000 Feb 15;42(3):239-42.
37. Harris TB, Ferrucci L, Tracy RP, et al. Associations of elevated
interleukin-6 and C-reactive protein levels with mortality in the
elderly. Am J Med. 1999 May;106(5):506-12.
38. Cappola AR, Xue Q-L, Ferrucci L, Guralnik JM, Volpato S, Fried
LP. Insulin- like growth factor I and interleukin-6 con- tribute synergistically
to disability and mor- tality in older women. J Clin Endocrinol Metab.
2003 May;88(5):2019-25.
39. Ferruci L, Harris TB, Guralnik JM, et al. Serum IL-6 level and
the development of disability in older persons. J Am Geriatr Soc.
1999 Jun;47(6):639-46.
40. Radack K, Deck C, Huster G. Dietary sup- plementation with low-dose
fish oils lowers fibrinogen levels. Ann Intern Med. 1989 Nov 1;111(9):757-8.
41. Folsom AR, Wu KK, Shahar E, Davis CE. Association of hemostatic
variables with prevalent cardiovascular disease and asymp- tomatic
carotid artery atherosclerosis. The Atherosclerosis Risk in Communities
(ARIC) Study Investigators. Arterioscler Thromb. 1993 Dec;13(12):1829-36.
42. Kyrle PA, Minar E, Hirschl M, et al. High plasma levels of factor
VIII and the risk of recurrent venous thromboembolism. N Engl J Med.2000
Aug 17;343(7):457-62. 43. Walston J, McBurnie MA, Newman A, et al.
Frailty and activation of the inflamma tion and coagulation systems
with and with out clinical comorbidities. Arch Intern Med. 2002 Nov
11;162(20):2333-41. 44. Burguera JL, Burguera M, Gallignani M, Alarcon
OM, Burgueera JA. Blood serum selenium in the province of Merida,
Venezuela, related to sex, cancer incidence and soil selenium content.
J Trace Elem Electrolytes Health Dis. 1990 Jun;4(2):73-7.
45. Mukoyama M, Nakao K, Hosoda K, et al. Brain natriuretic peptide
as a novel cardiac hormone in humans: evidence for an exqui site dual
natriuretic peptide system, atrial natriuretic peptide and brain natriuretic
peptide. J Clin Invest. 1991 Apr:87(4):1402-12.
46. Carillo-Jimenez R, Treadwell TL, Goldfine H, Buenano A, Lamas
GA, Hennekens CH. Brain natriuretic peptide and HIV-related cardiomyopathy.
AIDS Read. 2002 Nov;12(11):501-8.
47. Kawai K, Hata K, Takaoka H, Kawai H, Yokoyama M. Plasma brain
natriuretic pep- tide as a novel therapeutic indicator in idio- pathic
dilated cardiomyopathy during beta- blocker therapy: a potential of
hormone- guided treatment. Am Heart J. 2001 Jun;141(6):925-32.
48. Richards AM, Nicholls MG, Yandle TG, et al. Plasma N-terminal
pro-brain natriuretic peptide and adrenomedullin: new neuro- hormonal
predictors of left ventricular func- tion and prognosis after myocardial
infarc- tion. Circulation. 1998 May 19;97(19):1921- 9.
49. Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type
natriuretic peptide in the diagnosis of congestive heart failure in
an urgent-care setting. J Am Coll Cardiol. 2001 Feb;37(2):379-85.
50. Available at: http://www.lef.org/what shot /2001_02.html#hpfi.
Accessed March 10, 2004.
51. Cheng-Lai A, Levine A. Rosiglitazone: an agent from the thiazolidinedione
class for the treatment of type 2 diabetes. Heart Dis. 2000 Jul-Aug;2(4):326-33.
52. Krentz AJ, Bailey CJ, Melander A. Thiazolidinediones for type
2 diabetes. BMJ. 2000 Jul 29;321(7256):252-3.
53. Ogawa S, Takeuchi K, Ito S. Plasma BNP levels in the treatment
of type 2 diabetes with piglitazone. J Clin Endocrinol Metab. 2003
Aug;88(8):3993-6.
54. Burguera JL, Burguera M, Gallignani M, Alarcon OM, Burgueera
JA. Blood serum selenium in the province of Merida, Venezuela, related
to sex, cancer incidence and soil selenium content. J Trace Elem Electrolytes
Health Dis. 1990 Jun;4(2):73-7.
55. Fleet JC. Dietary selenium repletion may reduce cancer incidence
in people at high risk who live in areas with low soil selenium. Nutr
Rev. 1997 Jul;55(7):277-9.
56. Knekt P, Marniemi J, Teppo L, Heliovaara M, Aromaa A. Is low
selenium status a risk factor for lung cancer? Am J Epidemiol. 1998
Nov 15;148(10):975-82.
57. Patterson BH, Levander OA. Naturally occurring selenium compounds
in cancer chemoprevention trials: A workshop sum- mary. Cancer Epidemiol
Prev. 1997 Jan;6(1):63-9.
58. Russo MW, Murray SC, Wurzelmann JI, Woosley JT, Sandler RS. Plasma
selenium levels and the risk of colorectal adenomas. Nutr Cancer.
1997 ;28(2):125-9.
59. Shamberger RJ. The genotoxicity of seleni- um. Mutat Res.1985
Jul;154(1):29-48.
60. Young KJ, Lee PN. Intervention studies on cancer. Eur J Cancer
Prev. 1999 Apr;8(2):91-103.
61. Fleet JC. Dietary selenium repletion may reduce cancer incidence
in people at high risk who live in areas with low soil selenium. Nutr
Rev. 1997 Jul;55(7):277-9.
62. Bonora E, Kiechl S, Willeit J, et al. Prevalence of insulin
resistance in metabolic disorders: the Bruneck Study. Diabetes. 1998
Oct;47(10):1643-9.
63. Arad Y, Newstein D, Cadet F, Roth M, Guerci AD. Association
of multiple risk factors and insulin resistance with increased prevalence
of asymptomatic coronary artery disease by an electon-beam computed
tomographic study. Arterioscler Thromb Vasc Biol. 2001 Dec;21(12):2051-8.
64. Bonora E, Formentini G, Calcaterra F, et al. HOMA-estimated
insulin resistance is an independent predictor of cardiovascular disease
in Type II diabetic subjects. Prospective data from the Verona Diabetes
Complications Study. Diabetes Care. 2002 Jul;25(7):1135-41.
65. Available at:http://www.discover.pitt.edu/ media/pcc020916/sciInsulinResistant.html.
Accessed March 10, 2004.
66. Barton-Davis ER, Shoturma DI, Musaro A, Rosenthal N, Sweeney
HL. Viral mediated expression of insulin-like growth factor I blocks
the aging-related loss of skeletal muscle function. Proc Natl Acad
Sci. 1998 Dec 22;95(26):15603-7.
67. Ruiz-Torres A, Soares de Meo Kirzner M. Ageing and longevity
are related to growth hormone/insulin-like growth factor-1 secre-
tion. Gerontology. 2002 Nov-Dec;48(6);401- 7.
68. van den Beld AW, Bots ML, Janssen JA, Pols HA, Lamberts SW,
Grobbee DE. Endogenous hormones and carotid atherosclerosis in elderly
men. Am J Epidemiol. 2004 Jan 1;157(1):25-31.
69. Carro E, Trejo JL, Gomez-Isla T, LeRoith D, Torres-Aleman I.
Serum insulin-like growth factor I regulates brain amyloid-B levels.
Nature Medicine. 2002 Dec;8(12):1390-7.
70. Woodson K, Tangrea JA, Pollak M, et al. Serum insulin-like growth
factor I: tumor marker or etiologic factor? A prospective study of
prostate cancer among Finnish men. Cancer Res. 2003 Jul 15;63(14):3991-4.
71. Wilczak N, de Vos RAI, De Keyser J. Free insulin-like growth
factor (IGF)-1 and IGF binding proteins 2,5, and 6 in spinal motor
neurons in amyotrophic lateral sclerosis. Lancet. 2003 Mar 22;361(9362):1007-11.
72. Di Marzio L, Moretti S, D’Alo S, et al. Acetyl-L-carnitine
administration increases insulin-like growth factor 1 levels in asymp-
tomatic HIV-1-infected subjects: correlation with its suppressive
effect on lymphocyte apoptosis and ceramide generation. Clin Immunol.
1999 Jul;92(1):103-10.
73. Ladenson PW, Singer PA, Ain KB, et al. American Thyroid Association
guidelines for detection of thyroid dysfunction. Arch Intern Med.
2000 Jun 12;160(11):1573-5.
74. Vanderpump MP, Tunbridge WM, French JM et al. The incidence
of thyroid disorders in the community: a twenty-year follow-up of
the Whickham Survey. Clin Endocrinol. 1995 Jul;43(1):55-68.
75. Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman
JC. Subclinical hypothyroidism is an independ- ent risk factor for
atherosclerosis and myocardial infarction in elderly women: The Rotterdam
Study. Ann Intern Med. 2000 Feb 15;132(4):270-8.
76. Michalopoulou G, Alevizaki M, Piperingos G. et al. High serum
cholesterol levels in persons with “high-normal” TSH levels:
should one extend the definition of subclini- cal hypothyroidism.
Eur J Endocrinol. 1998 Feb;138(2):141-5.
77. Garnero P, Hausherr E, Chapey MC, et al. Markers of bone resorption
predict hip fracture in elderly women: The EPIDOS prospective study.
J Bone Min Res. 1996 Oct;11(10):1531-8.
78. Hesley RP, Shepard KA, Jankins DK, Riggs BL. Monitoring estrogen
replacement ther- apy and identifying rapid bone losers with an immunoassay
for deoxypyridinoline. Osteoporos Int.1998;8(2):159-64.
79. Scheidt-Nave C, Bismar H, Leidig-Bruckner G, et al. Serum inter-
leukin 6 is a major predictor of bone loss in women specific to the
first decade past menopause. J Clin Endocrinol Metab. 2001 May;86(5):2032-42.
80. Lakatos P, Foldes J, Horvath C, et al. Serum interleukin-6 and
bone metabolism in patients with thyroid function disorders. J Clin
Endocrinol Metab. 1997 Jan;82(1):78-81.
|